Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.03 - $7.81 $159,205 - $308,534
39,505 New
39,505 $283,000
Q1 2023

May 15, 2023

SELL
$3.74 - $7.46 $6,178 - $12,323
-1,652 Reduced 14.01%
10,140 $39,000
Q4 2022

Feb 14, 2023

SELL
$4.56 - $6.61 $42,330 - $61,360
-9,283 Reduced 44.05%
11,792 $60,000
Q3 2022

Nov 14, 2022

SELL
$3.75 - $6.63 $254,756 - $450,409
-67,935 Reduced 76.32%
21,075 $130,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $4.06 $36,859 - $70,924
-17,469 Reduced 16.41%
89,010 $336,000
Q1 2022

May 16, 2022

BUY
$2.73 - $11.94 $256,794 - $1.12 Million
94,064 Added 757.66%
106,479 $291,000
Q4 2021

Feb 14, 2022

BUY
$11.49 - $22.0 $142,648 - $273,130
12,415 New
12,415 $143,000

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $249M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.